MA50893A - Liants de facteur x renforçant l'activation fx - Google Patents
Liants de facteur x renforçant l'activation fxInfo
- Publication number
- MA50893A MA50893A MA050893A MA50893A MA50893A MA 50893 A MA50893 A MA 50893A MA 050893 A MA050893 A MA 050893A MA 50893 A MA50893 A MA 50893A MA 50893 A MA50893 A MA 50893A
- Authority
- MA
- Morocco
- Prior art keywords
- reinforcing
- activation
- binders
- factor
- factor binders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17201762 | 2017-11-15 | ||
| EP18174634 | 2018-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50893A true MA50893A (fr) | 2020-09-23 |
Family
ID=64426877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050893A MA50893A (fr) | 2017-11-15 | 2018-11-15 | Liants de facteur x renforçant l'activation fx |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11787874B2 (fr) |
| EP (2) | EP4667496A2 (fr) |
| JP (2) | JP7841846B2 (fr) |
| CN (2) | CN111386285B (fr) |
| ES (1) | ES3050257T3 (fr) |
| MA (1) | MA50893A (fr) |
| WO (1) | WO2019096874A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| JP7841846B2 (ja) * | 2017-11-15 | 2026-04-07 | ノヴォ ノルディスク アー／エス | Ｆｘ活性化を促進する第ｘ因子結合剤 |
| US10815308B2 (en) | 2018-12-21 | 2020-10-27 | Kymab Limited | FIXaxFX bispecific antibody with common light chain |
| JP2022548783A (ja) | 2019-09-23 | 2022-11-21 | ツイスト バイオサイエンス コーポレーション | 単一ドメイン抗体のバリアント核酸ライブラリー |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| JP2023106635A (ja) | 2020-04-17 | 2023-08-02 | 中外製薬株式会社 | 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法 |
| EP4314075A4 (fr) * | 2021-03-24 | 2025-04-09 | Twist Bioscience Corporation | Banques d'acides nucléiques variants pour cd3 |
| WO2023111018A1 (fr) * | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Anticorps contre le facteur de coagulation x et leurs utilisations |
| WO2023225035A2 (fr) * | 2022-05-16 | 2023-11-23 | Artisan Development Labs, Inc. | Compositions et méthodes d'ingénierie de cellules |
| US12098400B2 (en) * | 2022-07-08 | 2024-09-24 | Novo Nordisk A/S | Highly potent ISVD compounds capable of substituting for FVIII(A) |
| IL317317A (en) * | 2022-07-08 | 2025-01-01 | Novo Nordisk As | Highly potent ISVD compounds capable of replacing FVIII(A) |
| CN115960227A (zh) * | 2022-11-08 | 2023-04-14 | 河南赛诺特生物技术有限公司 | 一种抗人msh2的单克隆抗体及其制备方法和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| EP0368684B2 (fr) | 1988-11-11 | 2004-09-29 | Medical Research Council | Clonage de séquences d'immunoglobulines de domaines variables. |
| CA2143126A1 (fr) | 1993-07-01 | 1995-01-12 | Shamay Tang | Methode de preparation de plasma pauvre en facteur x |
| WO2000007626A1 (fr) | 1998-08-07 | 2000-02-17 | Smithkline Beecham Corporation | Utilisation d'anticorps de facteur anticoagulant comme agents protecteurs longue duree |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| WO2004041863A2 (fr) * | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Anticorps a domaine unique diriges contre un interferon gamma et leurs utilisations |
| US7461263B2 (en) | 2003-01-23 | 2008-12-02 | Unspam, Llc. | Method and apparatus for a non-revealing do-not-contact list system |
| WO2005035753A1 (fr) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | Anticorps a double specificite remplaçant une proteine fonctionnelle |
| ATE485307T1 (de) | 2003-11-07 | 2010-11-15 | Ablynx Nv | Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| PT1876236E (pt) | 2005-04-08 | 2014-10-22 | Chugai Pharmaceutical Co Ltd | Anticorpos para substituição da função do factor de coagulação sanguínea viii |
| WO2008020079A1 (fr) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Séquences d'acides aminés dirigées contre l'il-6r et polypeptides les contenant utilisés pour le traitement de maladies et de troubles associés au signal médié par il-6 |
| EP2915564B1 (fr) | 2007-09-28 | 2020-11-04 | Portola Pharmaceuticals, Inc. | Antidotes pour inhibiteurs du facteur XA et procédés d'utilisation associés |
| TWI452136B (zh) * | 2010-11-17 | 2014-09-11 | 中外製藥股份有限公司 | A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation |
| TWI831106B (zh) | 2014-06-20 | 2024-02-01 | 日商中外製藥股份有限公司 | 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物 |
| JP6698102B2 (ja) | 2015-04-17 | 2020-05-27 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 凝固因子と多重特異的抗体を用いた併用療法 |
| US20190185578A1 (en) | 2016-07-29 | 2019-06-20 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity |
| PL3509637T3 (pl) | 2016-09-06 | 2025-03-10 | Chugai Seiyaku Kabushiki Kaisha | Sposoby zastosowania dwuswoistego przeciwciała, które rozpoznaje czynnik krzepnięcia IX i/lub aktywowany czynnik krzepnięcia IX oraz czynnik krzepnięcia X i/lub aktywowany czynnik krzepnięcia X |
| TN2019000164A1 (en) | 2016-11-23 | 2020-10-05 | Bioverativ Therapeutics Inc | Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x |
| JP7841846B2 (ja) * | 2017-11-15 | 2026-04-07 | ノヴォ ノルディスク アー／エス | Ｆｘ活性化を促進する第ｘ因子結合剤 |
-
2018
- 2018-11-15 JP JP2020526504A patent/JP7841846B2/ja active Active
- 2018-11-15 US US16/764,124 patent/US11787874B2/en active Active
- 2018-11-15 CN CN201880073999.9A patent/CN111386285B/zh active Active
- 2018-11-15 ES ES18807239T patent/ES3050257T3/es active Active
- 2018-11-15 CN CN202411097090.0A patent/CN118745229A/zh active Pending
- 2018-11-15 EP EP25187342.8A patent/EP4667496A2/fr active Pending
- 2018-11-15 WO PCT/EP2018/081296 patent/WO2019096874A1/fr not_active Ceased
- 2018-11-15 MA MA050893A patent/MA50893A/fr unknown
- 2018-11-15 EP EP18807239.1A patent/EP3710486B1/fr active Active
-
2023
- 2023-09-06 US US18/242,868 patent/US20230416404A1/en active Pending
-
2025
- 2025-12-19 JP JP2025269754A patent/JP2026040534A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7841846B2 (ja) | 2026-04-07 |
| JP2026040534A (ja) | 2026-03-09 |
| US20210054097A1 (en) | 2021-02-25 |
| CN118745229A (zh) | 2024-10-08 |
| EP3710486A1 (fr) | 2020-09-23 |
| US20230416404A1 (en) | 2023-12-28 |
| CN111386285B (zh) | 2024-08-27 |
| ES3050257T3 (en) | 2025-12-19 |
| EP3710486B1 (fr) | 2025-10-08 |
| EP3710486C0 (fr) | 2025-10-08 |
| US11787874B2 (en) | 2023-10-17 |
| EP4667496A2 (fr) | 2025-12-24 |
| WO2019096874A1 (fr) | 2019-05-23 |
| JP2021502984A (ja) | 2021-02-04 |
| CN111386285A (zh) | 2020-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50893A (fr) | Liants de facteur x renforçant l'activation fx | |
| IL280648A (en) | Anti-galectin-9 antibodies and uses thereof | |
| IL272643A (en) | Binders | |
| IL262092B (en) | Humanized anti-pacap antibodies and uses thereof | |
| PL3420829T3 (pl) | Kompozytowe knoty do mikrowaporyzatora | |
| HRP20181802T1 (hr) | Protutijela koja vežu humani cd3 | |
| LT3571224T (lt) | Patobulintos serumo albumino rišamosios medžiagos | |
| EP3664752A4 (fr) | Libération de stent | |
| DK3574016T3 (da) | Nkp46-bindingsmidler | |
| EP3661961A4 (fr) | Anticorps se liant à l'alpha-synucléine active | |
| CL2018000650S1 (es) | Sujetador. | |
| CL2018000651S1 (es) | Sujetador y pinza. | |
| EP3876776C0 (fr) | Connecteur | |
| IL268288A (en) | Binders | |
| EP3713521A4 (fr) | Implant rachidien | |
| EP3765265A4 (fr) | Agent liant | |
| EP3691553C0 (fr) | Implant rachidien | |
| EP3794015A4 (fr) | Agents d'activation | |
| EP3670763A4 (fr) | Système hydraulique | |
| EP3836166A4 (fr) | Corps composite | |
| DK3398661T3 (da) | Netindretning | |
| EP3681598C0 (fr) | Système d'implant | |
| EP3815871A4 (fr) | Composite | |
| EP3815819A4 (fr) | Composite | |
| EP3566007C0 (fr) | Réchaud |